MMP9 Antibodies

Structure of MMP9

MMP-9 is a medium-sized protein with a molecular weight of approximately 92 kDa, and its molecular weight varies among different species.

MMP-9 maintains its proenzyme state through its cysteine switch (Cys99). When this region is proteolytic and excised, the enzyme active center is exposed, thereby acquiring the ability to degrade extracellular matrix components such as type IV collagen. This activation mechanism enables it to play a key role in tissue remodeling and pathological processes.

Fig. 1 A schematic representation of the MMP9 gene and protein organization.¹

Fig. 2 Schematic representation of the signaling pathways involved in MMP9 expression.¹

Key structural properties of MMP9:

• Amino-terminal signal peptide
• Propeptide domain
• Catalytic domain
• Hinge area
• Heme-binding protein-like domains

Functions of MMP9

The main function of MMP-9 is to degrade extracellular matrix and participate in various physiological and pathological processes.

The activity regulation of MMP-9 presents a typical "all or none" feature, and its proenzyme needs to be activated by proteolysis to exert its function. Compared with other matrix metalloproteinases, MMP-9 has higher specificity for gelatin substrates. This substrate selectivity enables it to play a unique role in pathological processes. The activity of this enzyme is specifically inhibited by TIMP-1, and this 1:1 inhibition ratio constitutes the key mechanism for in vivo balance regulation.

Applications of MMP9 and MMP9 Antibody in Literature

1. Augoff, Katarzyna, et al. "MMP9: a tough target for targeted therapy for cancer." Cancers 14.7 (2022): 1847. https://doi.org/10.3390/cancers14071847

The article indicates that MMP9 promotes tumor invasion and metastasis by degrading the extracellular matrix and is an important target for cancer treatment. Recently, selective MMP9 antibody inhibitors have made breakthroughs and are undergoing clinical trials, bringing new hope to targeted therapy. However, further exploration of their regulatory mechanisms is still needed to enhance therapeutic efficacy.

2. Ryu, Jina, et al. "Development of a CHO cell line for stable production of recombinant antibodies against human MMP9." BMC biotechnology 22.1 (2022): 8. https://doi.org/10.1186/s12896-022-00738-6

In this study, a high-purity and high-sensitivity recombinant anti-HMMP9 antibody was successfully developed using the CHO cell expression system, and its efficient antigen binding ability was verified, providing a new antibody tool for the diagnosis and treatment of diseases such as cancer.

3. Juric, Vladi, et al. "MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors." PLoS One 13.11 (2018): e0207255. https://doi.org/10.1371/journal.pone.0207255

The mouse anti-MMP-9 monoclonal antibody developed in this study can inhibit the growth of HER2-positive breast cancer and enhance the immunotherapeutic effect of PD-L1 antibody by up-regulating T cell chemokines such as CXCL10. The combined treatment significantly increases the proportion of tumor-infiltrating memory/effector T cells and improves the immunosuppressive microenvironment.

4. Appleby, Todd C., et al. "Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9." Journal of Biological Chemistry 292.16 (2017): 6810-6820. https://doi.org/10.1074/jbc.M116.760579

This study resolved the crystal structure of the humanized monoclonal antibody GS-5745 complex with MMP9, revealing its dual inhibition mechanism by binding to the distal site of the enzyme: it not only prevents the activation of MMP9 but also allosterically inhibits its catalytic activity, providing a new targeted strategy for the treatment of inflammation and tumors.

5. Awasthi, Niranjan, et al. "Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer." Journal of cellular and molecular medicine 23.6 (2019): 3878-3887. https://doi.org/10.1111/jcmm.14242

This study analyzed that the combination of anti-MMP9 antibody and nab- paclitaxel/gemcitabine significantly prolonged the survival period of pancreatic cancer models (with a maximum increase of 218%), exerting a specific targeting effect on the tumor microenvironment by reducing the expression of interstromal collagen and αSMA and increasing the level of IL-28, providing a new strategy for clinical combined treatment.

Creative Biolabs: MMP9 Antibodies for Research

Creative Biolabs specializes in the production of high-quality MMP9 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MMP9 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MMP9 antibodies, custom preparations, or technical support, contact us at email.